Answer
MabThera (rituximab), in combination with methotrexate, is indicated for adults with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs, including one or more tumour necrosis factor inhibitor therapies.
Sources for this answer
- MabThera 100mg and 500mg Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 57Document updated
Sources checked